$MIRM

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. (the “Company”)

Mirum Pharmaceuticals reported positive Phase 2 results for ATEBRIOZ in children aged 6-12 with FOP. Bone lesion volume decreased by 8.09 cm³ with treatment vs. a 9.14 cm³ increase with placebo. No new lesions formed, and joint mobility improved. The company plans to submit a supplemental NDA in early 2027. MIRM stock is up 1.46% at $81.56.

TD Cowen kept a Buy rating on Mirum Pharmaceuticals with a $145 price target, implying a 70.4% upside from the Oct 20 close. The firm cited Mirum's strong pipeline, including Livmarli, and positive analyst sentiment as key factors.

Mirum Pharmaceuticals' maralixibat (Livmarli) showed gastrointestinal side effects in the phase 3 EXPAND trial for ultra-rare cholestatic liver diseases. Diarrhea occurred in 64.0% of patients vs 11.1% on placebo, with other adverse events including abdominal pain and increased alanine aminotransferase. The drug improved pruritus symptoms significantly. Mirum plans to submit a supplemental new drug application in 2027 based on EXPAND results.

Mirum Pharmaceuticals' maralixibat (Livmarli) significantly reduced cholestatic pruritus in the phase 3 EXPAND trial, with a 0.98-point improvement in itch severity (P = .0004) and 69% decrease in serum bile acids. The trial enrolled 52 patients with ultra-rare cholestatic liver diseases. Results were announced by the company on October 12, 2026.

Stifel raised its price target for Mirum Pharmaceuticals (MIRM) to $156 from $136, citing recent clinical and regulatory achievements. The stock trades at $82.64, with strong revenue growth of 44% over the last year, reaching $618 million. Analysts highlight multiple expansion opportunities and a potential peak portfolio value of over $4 billion. The stock has declined 17% over the past six months, but analysts maintain a positive outlook.

Evercore ISI Group maintained an Outperform rating for Mirum Pharmaceuticals (MIRM) and raised its price target from $135.00 to $146.00. The company's GF Value is $82.70, suggesting it is 1.7% undervalued. Mirum has a GF Score of 51/100, with strong momentum but weak profitability. Insiders have sold $10.78 million in shares over the last three months.

Mirum Pharmaceuticals reported that its drug maralixibat met the primary endpoint in the Phase 3 EXPAND trial, showing significant improvement in cholestatic pruritus. All secondary endpoints were also met, including reductions in serum bile acids. The company plans to submit a U.S. supplemental NDA in the first half of 2027. According to the company, safety data were consistent with prior experience.

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Data from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMAR